



Xintela AB changes Certified Adviser to Tapper Partners AB

Xintela AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.

Xintela AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser. Tapper Partners AB will assume the role of Certified Adviser on August 15, 2025. Until then, DNB Carnegie Investment Bank AB will continue to act as the company's Certified Adviser.

Contacts

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin $\alpha 10\beta 1$ which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin $\alpha 10\beta 1$ (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is DNB Carnegie Investment Bank AB.

Press Release
11 August 2025 15:01:00 CEST



Attachments

[Xintela AB changes Certified Adviser to Tapper Partners AB](#)